loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Cipla has entered into exclusive licensing and supply agreement with Qilu Pharmaceutical for QL2107

ICICIdirect Research 04 Sep 2026 DISCLAIMER

News: Cipla has entered into exclusive licensing and supply agreement with Qilu Pharmaceutical for QL2107, a biosimilar to cancer drug Keytruda (pembrolizumab), in the US. Qilu will handle development, regulatory filings and supply, while Cipla will commercialise the product, subject to regulatory approval.

View: The deal marks an important milestone for Cipla as bKetruda could be a sizable future opportunity (US$ 19 billion) despite impending competition with several global players (including Indian players such as Zydus, Biocon, DRL) vying for this. We will keep tabs on the USFDA readouts as the core patent is set to expire in December 2028.  

Impact: Positive

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere